Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Godby

Showing results (131-140 of 154) with videos related to

Pageof 16
Sort By:
American Journal of Hematology|March 28, 2026
Thirty Years of Classical Hematology Drugs in the US: Approvals, Costs, and SalesLucas T Go, Lewis T Go, Michelle A Elliott, et al.
Cancer Causes & Control : CCC|November 25, 2015
Family history of hematologic malignancies and risk of multiple myeloma: differences by race and clinical featuresMaryAnn E VanValkenburg, Gwendolyn I Pruitt, Ilene K Brill, et al.
Blood Advances|August 12, 2025
Assessment of Classical Hematologists and Classical Hematology Fellowship Programs at NCI-Designated Cancer CentersLewis T Go, Lucas T Go, Madugodaralalage Dsk Gunaratne, et al.
Clinical Lymphoma, Myeloma & Leukemia|November 29, 2021
Comparison of Cilta-cel, an Anti-BCMA CAR-T Cell Therapy, Versus Conventional Treatment in Patients With Relapsed/Refractory Multiple MyelomaLuciano J Costa, Yi Lin, R Frank Cornell, et al.
Histology and Histopathology|June 10, 2005
Karyotypic analysis of adult pluripotent stem cellsN L Henson, M L Heaton, B H Holland, et al.
Blood|September 22, 2023
Tafasitamab and lenalidomide in large B-cell lymphoma: real-world outcomes in a multicenter retrospective studyDavid A Qualls, Nicholas Lambert, Paolo F Caimi, et al.
Hemasphere|November 20, 2025
Outcomes of tafasitamab and lenalidomide in large B-cell lymphoma based on prior CD19-directed CAR T exposureMwanasha H Merrill, Robert A Redd, Nicholas Lambert, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|January 6, 2022
NCCN Guidelines® Insights: Multiple Myeloma, Version 3.2022Natalie S Callander, Muhamed Baljevic, Kehinde Adekola, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|January 18, 2023
Systemic Light Chain Amyloidosis, Version 2.2023, NCCN Clinical Practice Guidelines in OncologyShaji K Kumar, Natalie S Callander, Kehinde Adekola, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|December 7, 2020
Multiple Myeloma, Version 3.2021, NCCN Clinical Practice Guidelines in OncologyShaji K Kumar, Natalie S Callander, Kehinde Adekola, et al.
Pageof 16

Showing results (131-140 of 154) with videos related to

Sort By:
Pageof 16
American Journal of Hematology|March 28, 2026
Thirty Years of Classical Hematology Drugs in the US: Approvals, Costs, and SalesLucas T Go, Lewis T Go, Michelle A Elliott, et al.
Cancer Causes & Control : CCC|November 25, 2015
Family history of hematologic malignancies and risk of multiple myeloma: differences by race and clinical featuresMaryAnn E VanValkenburg, Gwendolyn I Pruitt, Ilene K Brill, et al.
Blood Advances|August 12, 2025
Assessment of Classical Hematologists and Classical Hematology Fellowship Programs at NCI-Designated Cancer CentersLewis T Go, Lucas T Go, Madugodaralalage Dsk Gunaratne, et al.
Clinical Lymphoma, Myeloma & Leukemia|November 29, 2021
Comparison of Cilta-cel, an Anti-BCMA CAR-T Cell Therapy, Versus Conventional Treatment in Patients With Relapsed/Refractory Multiple MyelomaLuciano J Costa, Yi Lin, R Frank Cornell, et al.
Histology and Histopathology|June 10, 2005
Karyotypic analysis of adult pluripotent stem cellsN L Henson, M L Heaton, B H Holland, et al.
Blood|September 22, 2023
Tafasitamab and lenalidomide in large B-cell lymphoma: real-world outcomes in a multicenter retrospective studyDavid A Qualls, Nicholas Lambert, Paolo F Caimi, et al.
Hemasphere|November 20, 2025
Outcomes of tafasitamab and lenalidomide in large B-cell lymphoma based on prior CD19-directed CAR T exposureMwanasha H Merrill, Robert A Redd, Nicholas Lambert, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|January 6, 2022
NCCN Guidelines® Insights: Multiple Myeloma, Version 3.2022Natalie S Callander, Muhamed Baljevic, Kehinde Adekola, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|January 18, 2023
Systemic Light Chain Amyloidosis, Version 2.2023, NCCN Clinical Practice Guidelines in OncologyShaji K Kumar, Natalie S Callander, Kehinde Adekola, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|December 7, 2020
Multiple Myeloma, Version 3.2021, NCCN Clinical Practice Guidelines in OncologyShaji K Kumar, Natalie S Callander, Kehinde Adekola, et al.
Pageof 16